| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192557 | Annals of Allergy, Asthma & Immunology | 2009 | 8 Pages |
Abstract
Ciclesonide hydrofluoroalkane nasal aerosol demonstrated statistically significant improvements in SAR symptoms vs placebo. On the basis of comparable efficacy and safety profiles observed for all doses, these results suggest that the 75-μg and 150-μg doses of ciclesonide hydrofluoroalkane appear appropriate for further evaluation of efficacy.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Craig MD, Julius MD, Eli O. MD, Mark A. PhD,